HUE050904T2 - Idõben fokozatos felszabadítású biológiailag lebontható vagy biológiailag erodeálódó mikrogömbök vagy mikrorészecskék, melyek egy megszilárduló depó-képzõ injekciós gyógyszerben vannak szuszpendálva - Google Patents

Idõben fokozatos felszabadítású biológiailag lebontható vagy biológiailag erodeálódó mikrogömbök vagy mikrorészecskék, melyek egy megszilárduló depó-képzõ injekciós gyógyszerben vannak szuszpendálva

Info

Publication number
HUE050904T2
HUE050904T2 HUE13702182A HUE13702182A HUE050904T2 HU E050904 T2 HUE050904 T2 HU E050904T2 HU E13702182 A HUE13702182 A HU E13702182A HU E13702182 A HUE13702182 A HU E13702182A HU E050904 T2 HUE050904 T2 HU E050904T2
Authority
HU
Hungary
Prior art keywords
drug formulation
injectable drug
time released
microparticles suspended
bioerodible microspheres
Prior art date
Application number
HUE13702182A
Other languages
English (en)
Inventor
David Marsh
Hongwen Ma Rivers
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HUE050904T2 publication Critical patent/HUE050904T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
HUE13702182A 2012-01-23 2013-01-22 Idõben fokozatos felszabadítású biológiailag lebontható vagy biológiailag erodeálódó mikrogömbök vagy mikrorészecskék, melyek egy megszilárduló depó-képzõ injekciós gyógyszerben vannak szuszpendálva HUE050904T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23

Publications (1)

Publication Number Publication Date
HUE050904T2 true HUE050904T2 (hu) 2021-01-28

Family

ID=47630595

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13702182A HUE050904T2 (hu) 2012-01-23 2013-01-22 Idõben fokozatos felszabadítású biológiailag lebontható vagy biológiailag erodeálódó mikrogömbök vagy mikrorészecskék, melyek egy megszilárduló depó-képzõ injekciós gyógyszerben vannak szuszpendálva

Country Status (18)

Country Link
US (3) US20130189369A1 (hu)
EP (1) EP2806853B1 (hu)
JP (1) JP6282231B2 (hu)
KR (5) KR20220044379A (hu)
CN (1) CN104136006B (hu)
AU (3) AU2013212583A1 (hu)
BR (1) BR112014017969A8 (hu)
CA (1) CA2861348C (hu)
DK (1) DK2806853T3 (hu)
ES (1) ES2821526T3 (hu)
HK (1) HK1204765A1 (hu)
HU (1) HUE050904T2 (hu)
IL (2) IL233620A0 (hu)
MX (1) MX364864B (hu)
NZ (1) NZ627368A (hu)
RU (1) RU2672596C2 (hu)
WO (1) WO2013112434A1 (hu)
ZA (1) ZA201405091B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
WO2017053346A1 (en) 2015-09-21 2017-03-30 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EA038755B1 (ru) 2015-11-12 2021-10-14 Грейбаг Вижн, Инк. Агрегирующие микрочастицы для обеспечения замедленного высвобождения терапевтического агента для внутриглазной доставки
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
MX2020000376A (es) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc Formulaciones farmaceuticas hipercomprimidas.
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送***及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
EP4277661A1 (en) 2021-01-18 2023-11-22 Anton Frenkel Pharmaceutical dosage form
WO2022198167A1 (en) * 2021-03-15 2022-09-22 Oakwood Laboratories, Llc Microsphere formulations comprising naltrexone and methods for making and using the same
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP1125577B1 (en) * 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
CA2275525C (en) * 1996-12-20 2011-02-08 Kevin J. Brodbeck Gel composition and methods
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
EP1568359A4 (en) * 2002-12-04 2011-05-18 Santen Pharmaceutical Co Ltd DRUG DELIVERY SYSTEM HAVING SUB-CONJUNCTIVAL DEPOSIT
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
WO2009001697A2 (en) * 2007-06-25 2008-12-31 Otsuka Pharmaceutical Co., Ltd. Microspheres having core/shell structure
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法

Also Published As

Publication number Publication date
AU2017258895B2 (en) 2019-04-18
EP2806853A1 (en) 2014-12-03
EP2806853B1 (en) 2020-07-08
NZ627368A (en) 2016-11-25
CA2861348A1 (en) 2013-08-01
MX2014008857A (es) 2015-07-17
AU2013212583A1 (en) 2014-08-14
RU2014134420A (ru) 2016-03-20
AU2017258895A1 (en) 2017-11-30
KR102183727B1 (ko) 2020-11-27
MX364864B (es) 2019-05-09
IL233620A0 (en) 2014-08-31
JP6282231B2 (ja) 2018-02-21
KR20200073292A (ko) 2020-06-23
KR20230104761A (ko) 2023-07-10
RU2672596C2 (ru) 2018-11-16
ZA201405091B (en) 2015-12-23
CN104136006A (zh) 2014-11-05
US20130189369A1 (en) 2013-07-25
ES2821526T3 (es) 2021-04-26
IL265620A (en) 2019-05-30
US20200297650A1 (en) 2020-09-24
KR20220044379A (ko) 2022-04-07
KR20200133286A (ko) 2020-11-26
CN104136006B (zh) 2017-11-24
HK1204765A1 (en) 2015-12-04
WO2013112434A1 (en) 2013-08-01
CA2861348C (en) 2017-07-04
US20230390212A1 (en) 2023-12-07
IL265620B (en) 2022-03-01
BR112014017969A2 (hu) 2017-06-20
AU2019204957A1 (en) 2019-07-25
DK2806853T3 (da) 2020-09-28
KR20140114892A (ko) 2014-09-29
JP2015504098A (ja) 2015-02-05
BR112014017969A8 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
IL265620B (en) Sustained-release biodegradable or chewable microspheres or microparticles suspended in an injectable drug formulation produce a solidified precipitate
SG11201406799XA (en) A delayed release drug formulation
EP2701687A4 (en) RISERIDONE MICROSPHERES COMPOSITION WITH EXTENDED RELEASE
IL240148A0 (en) Biodegradable and clinically compatible nanoparticles as drug delivery carriers
HK1222547A1 (zh) 延遲釋放的藥物製劑
HRP20190470T1 (hr) Formulacija lijeka s odgođenim otpuštanjem
PL2987484T3 (pl) Kompozycja farmaceutyczna mikrosfery o przedłużonym uwalnianiu gosereliny
EP2897597A4 (en) BIODEGRADABLE MULTI-LAYER MICROPARTICLES FOR PROLONGED RELEASE OF THERAPEUTIC AGENTS
TWI559972B (en) Microparticle and addition agent
GB201300437D0 (en) Injectable Active Ingredient Release Compositions and Methods for Their Production and Use
GB201205083D0 (en) Gravity anchor